论文部分内容阅读
本研究应用放射配基法检测了胃癌及大肠癌各35例癌组织中的雌激素受体(ED)水平,并分析了非雌激素靶器官的胃癌及大肠癌中ER的阳性率与其某些临床病理变化之间的关系。结果:70例胃癌及大肠癌中21例呈ER阳性,阳性率为30％,其中胃癌的ER阳性率为25.7％,大肠癌34.3％。胃癌ER多发生于大体标本为BorrmannⅢ型,组织学上则以低分化腺癌多见;大肠癌ER阳性在DukeC级有增多的趋势,组织学上则表现为细胞分化程度越高,ER阳性率越高。本研究表明:部分胃癌及大肠癌中出现的ER提高这些肿瘤的发生及发展过程中可能与性激素有关,因此对某些晚期或因复发而失去手术根治机会的胃癌及大肠癌,采取内分泌治疗作为一种新型的辅助治疗手段具有广阔的前景。
In this study, the levels of estrogen receptor (ED) in 35 cases of gastric cancer and colorectal carcinoma were detected by radioligand assay, and the positive rates of ER in gastric cancer and colorectal cancer in non-estrogen target organs were analyzed. The relationship between clinical pathological changes. Results: Among the 70 cases of gastric cancer and colorectal carcinoma, 21 cases were positive for ER, and the positive rate was 30%. Among them, ER positive rate of gastric cancer was 25.7%, and colorectal cancer was 34.3%. Gastric cancer ER mostly occurred in the gross specimen Borrmann type III. Histologically, poorly differentiated adenocarcinoma was more common. ER positive of colorectal cancer showed a tendency of increasing at Duke C level. Histologically, ER positive rate showed higher degree of cell differentiation. The higher. This study shows that: ER in some gastric cancer and colorectal cancer may increase the occurrence and development of these tumors may be related to sex hormones, so for certain advanced or recurrence of cancer and colon cancer lose the chance of radical surgery, endocrine therapy as A new type of adjuvant therapy has broad prospects.